JNJ ▼ -1.6% - Johnson & Johnson $JNJ - Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026 Johnson & Johnson shares fell 1.6% today despite the company presenting new neuropsychiatry data on bipolar mania, depression, and schizophrenia treatments at Psych Congress 2026. The decline suggests investors may have had higher expectations for the clinical data, or that broader market conditions outweighed positive developments in the company's psychiatric drug pipeline. 08-SEP-2026 08:01 AM ET